Predictive Biomarkers in Patients With Advanced Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab

Sponsor
CHA University
Study ID
NCT05173298
Status
Unknown

Conditions

  • Advanced Hepatocellular Carcinoma

Eligibility Criteria

Sex
ALL
Age
19 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The goal of this observational study is to learn about in patients with advanced hepatocellular carcinoma treated with atezoliozumab and bevacizumab. In this clinical study, we intend to analyze the multiomics data by analyzing the peripheral blood and tumor tissue before and after treatment of patients with advanced liver cancer receiving systemic drug treatment, and analyzing the correlation with the treatment. This is an exploratory study that aims to discover biomarkers that are highly correlated with treatment response.

Key Dates

Start date
Aug 2, 2021
Status verified
Feb 2024
Primary completion
Jul 31, 2024
Completion
Dec 31, 2024

Study Design

Enrollment
100 participants (estimated)

Arms

  • Arm: analytic group
    advanced HCC Patients

Primary Outcome Measure

collected tumor samples [ Time Frame: through study completion, an average of 3 years ]

Central Contacts

Related Studies